mortality/aging
• most die within 2 weeks of birth
|
growth/size/body
• about half are smaller than controls
• half the size of controls
|
hematopoietic system
• decreased myeloid (CFU-GM, 18-fold) progenitors in yolk sacs
• decreased multipotential (CFU-GEMM, 10-fold) progenitors in yolk sacs
• normal primitive hematopoiesis
|
• decreased erythroid (BFU-E, 10-fold)
• decreased granulocyte macrophage (CFU-GM, 32-fold)
• decreased granulocyte macrophage/macrophage (CFUGM/M, 14-fold)
• decreased multipotential (CFU-GEMM, 14-fold) progenitor cells
|
• multinodular erythropoiesis in the spleen
|
• hypocellular bone marrow
• a 2-fold decrease in the percentage of myeloid cells
• decreased Lin-/Sca-1-/c-Kit+ (LSK) bone marrow cells (include hematopoietic stem cells)
|
• 2.3 fold reduction in number
|
• 1.6 fold reduction
|
• 1.6 fold reduction
|
• 11 fold decrease in platelet count
|
• 2.1 fold reduction in number
|
• 5.4 fold reduction in neutrophils
|
pancytopenia
(
J:152911
)
• myeloid and megakaryocyte cell populations are decreased 4-fold and 14-fold
|
• both the short- and longer-term reconstituting capacities of fetal liver cells are greatly compromised
|
liver/biliary system
• decreased nucleated cellularity in the fetal liver
|
pale liver
(
J:152911
)
renal/urinary system
pale kidney
(
J:152911
)
cardiovascular system
hemorrhage
(
J:152911
)
• pallor of the skin, liver, and kidneys in necropsied mice, often accompanied by overt hemorrhage
|
• frequent intestinal hemorrhage
|
• subcutaneous hemorrhages often visible in living mice
|
immune system
• 2.1 fold reduction in number
|
• 5.4 fold reduction in neutrophils
|
• myeloid and megakaryocyte cell populations are decreased 4-fold and 14-fold
|
embryo
• decreased myeloid (CFU-GM, 18-fold) progenitors in yolk sacs
• decreased multipotential (CFU-GEMM, 10-fold) progenitors in yolk sacs
• normal primitive hematopoiesis
|
digestive/alimentary system
• frequent intestinal hemorrhage
|
integument
• subcutaneous hemorrhages often visible in living mice
|